Zobrazeno 1 - 10
of 44
pro vyhledávání: ''
Publikováno v:
Journal of Ovarian Research, Vol 15, Iss 1, Pp 1-13 (2022)
Journal of Ovarian Research
Journal of Ovarian Research
Background Tripartite Motif-Containing 24 (TRIM24) is a member of the tripartite motif family. TRIM24 is claimed aberrantly activated in a number of cancers, such as breast cancer, prostate cancer and lung cancer. However, the expression of TRIM24 in
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-15 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background Circular RNA (circRNA) is recently found to participate in the regulation of tumor progression, including ovarian cancer. However, the application of circRNA SET domain bifurcated histone lysine methyltransferase 1 (circSETDB1) as a therap
Autor:
Yu-Jie Dong, Qi Yang
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-13 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
BackgroundOvarian cancer (OC) is characterized by early metastasis and poor prognosis, which threatens the health of women worldwide. Small nucleolar RNA host gene 20 (SNHG20), a long noncoding RNA (lncRNA), has been verified to be significantly up-r
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-9 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background ETS transcription factors are known to act as either positive or negative regulators of the expression of genes involved in various biological processes. It was reported that ETS variant transcription factor 5 (ETV5), a key member of the E
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-13 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background Small nucleolar RNA host gene 25 (SNHG25), a long noncoding RNA, has been well-studied in epithelial ovarian cancer. However, the specific functions of SNHG25 in endometrial cancer (EC) have not been studied yet. In this study, we aimed to
Autor:
Guoliang Yan, Can Zhao, Yun Leng, Xin Li, Ting Gong, Ying-Gui Yang, Chenglin Li, Shuangyue Xu
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-12 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background Resistance to platinum-based chemotherapy is one of the crucial problems in ovarian cancer treatment. Ghrelin, a widely distributed peptide hormone, participates in a series of cancer progression. The aim of this study is to determine whet
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-14 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background Ovarian cancer is the most lethal gynecologic malignancy worldwide. Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), is becoming widely used in ovarian cancer treatment. The overall survival of ovarian cancer has not been sig
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-11 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Objective TCP1 is one of the eight subunits of the TCP1 ring complex (TRiC) or the multi-protein mammalian cytosolic chaperone complex. TRiC participates in protein folding and regulates the expression of multiple signaling proteins and cytoskeletal
Autor:
Ofer Reizes, Peter G. Rose, Justin D. Lathia, Goutam Dey, Soumya M. Turaga, Caner Saygin, Katie K. Crean-Tate, Chad M. Michener, Emily Esakov, Daniel J. Silver, Alexandria Trestan, Elizabeth V. Connor, Robert Debernardo, Chad Braley
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-10 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background Ovarian cancer is the most fatal gynecologic malignancy in the United States. While chemotherapy is effective in the vast majority of ovarian cancer patients, recurrence and resistance to standard systemic therapy is nearly inevitable. We
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-11 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background Propofol is a kind of common intravenous anaesthetic agent that plays an anti-tumor role in a variety of cancers, including ovarian cancer. However, the working mechanism of Propofol in ovarian cancer needs further exploration. Methods The